The FDA has approved dexmedetomidine (IGALMI, BioXcel Therapeutics) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.
FDA Approvals
FDA Approvals
FDA Okays First Sublingual Med for Agitation in Schizophrenia, BD
The FDA has approved dexmedetomidine (IGALMI, BioXcel Therapeutics) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.
FDA Approvals
FDA Approvals